Seagen touts progress for Pad­cev and Tukysa as it con­tin­ues CEO search

De­spite ru­mors swirling around a po­ten­tial buy­out, Seagen’s fo­cus­ing on good news for its key drugs while con­tin­u­ing to search for a more per­ma­nent CEO.

That in­cludes Pad­cev, which post­ed pos­i­tive topline da­ta in com­bi­na­tion with Keytru­da as a first-line ther­a­py for ad­vanced blad­der can­cer at ES­MO this year. Charles Romp, EVP of com­mer­cial for the US, told in­vestors on the Q3 call on Thurs­day that com­mer­cial teams are prepar­ing for a po­ten­tial launch in the mid­dle of 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER